✦ LIBER ✦

Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study

✍ Scribed by Shannon Allen Ferrante, Jagpreet Chhatwal, Clifford A Brass…

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Personalized cost-effectiveness of bocep

✍ Petta, S.; Cabibbo, G.; Enea, M.; Macaluso, F.S.; Plaia, A.; Bruno, R.; Gasbarri 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Personalized cost-effectiveness of bocep

✍ Petta, Salvatore; Cabibbo, Giuseppe; Enea, Marco; Macaluso, Fabio Salvatore; Pla 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 998 KB

Cost-effectiveness of boceprevir or tela

✍ Cammà, Calogero; Petta, Salvatore; Cabibbo, Giuseppe; Ruggeri, Matteo; Enea, Mar 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 277 KB

Cost-effectiveness of sofosbuvir-based t

✍ Petta, S.; Cabibbo, G.; Enea, M.; Macaluso, F.S.; Plaia, A.; Bruno, R.; Gasbarri 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 58 KB

Cost-effectiveness of sofosbuvir-based t

✍ Petta, Salvatore; Cabibbo, Giuseppe; Enea, Marco; Macaluso, Fabio Salvatore; Pla 📂 Article 📅 2014 🏛 John Wiley and Sons 🌐 English ⚖ 868 KB

Boceprevir With Peginterferon Alfa-2aâ

✍ Flamm, Steven L.; Lawitz, Eric; Jacobson, Ira; BourliÃ¨re, Marc; Hezode, Christo 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 732 KB